SAN DIEGO, Calif. – January 6, 2020 – A study by Millennium Health published in JAMA Network Open reports that since 2016, rates of positive definitive urine drug test (UDT) results have increased significantly by 42.44% for methamphetamine and 75.46% for fentanyl. This is in sharp contrast to cocaine and heroin, where positivity peaked in 2016 and has since declined by 3.70% and 21.65%, respectively. The results also revealed that among UDT results positive for fentanyl, methamphetamine positivity continued to increase after 2016 by 153.51%.
Our Latest News
SAN DIEGO, Calif. – July 17, 2019 – Millennium Health, a leader in identifying and responding to illicit and prescription drug use trends, has expanded its urine drug test offering to include fentanyl analogues. Up to 10,000-fold more potent than morphine,¹ and often spiked into, or used concomitantly with heroin, cocaine or methamphetamine, these analogues pose a serious risk for overdose.Read More
SAN DIEGO, Calif. – May 1, 2019 – A study published in JAMA Network Open reports that between January 2013 and September 2018, the presence of non-prescribed fentanyl among urine drug tests also positive for cocaine or methamphetamine rose 1850% and 798% respectively. This analysis provides the public with additional insight into trending increases in reported cocaine- and methamphetamine-related overdoses. Cocaine and methamphetamine related drug overdose deaths are rising sharply. These data suggest the increase may be related to the simultaneous presence of fentanyl, either added directly to the drug supply or used concomitantly.
SAN DIEGO, Calif. – March 6, 2019 – Millennium Health, in close collaboration with independent clinical experts, has analyzed its proprietary database of millions of drug test results from the last five years to answer some of the most pressing questions associated with trends in medication use and substance abuse today.
SAN DIEGO, Calif. – February 27, 2018 – Millennium Health, a leading health solutions company, is pleased to announce the appointment of Andrew A. Lukowiak, Ph.D. as Chief Executive Officer (CEO) effective March 1, 2018. Dr. Lukowiak has nearly 20 years of management experience in molecular diagnostics and most recently served as the Chief Operating Officer (COO) and interim-CEO of a privately held precision medicine company, where he had been a part of the management team since 2013.
(RADAR® / MAPP® Hotline)
Monday–Friday 5:00AM-5:30PM PT